BioCentury | May 21, 2020
Finance

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

...kinase C θ S6K1 (RPS6KB1) - Ribosomal protein S6 kinase 70kDa polypeptide 1 Paul Bonanos, Associate Editor HotSpot Therapeutics Inc. Ribosomal protein S6...
BioCentury | Nov 21, 2019
Financial News

Nov. 20 Financial Quick Takes: Diagnostics play Lucence raises series A; plus Novo-Broad, PMV, Phoenix, Winterlight and BMS-Celgene

...trial of its first clinical candidate, PMD-026, to treat triple-negative breast cancer. The therapy targets ribosomal protein S6...
BioCentury | Feb 22, 2019
Targets & Mechanisms

Expansion into TNBC

...myelocytomatosis viral oncogene homolog OTULIN - OTU deubiquitinase with linear linkage specificity RSK2 (RPS6KA3) - Ribosomal protein S6...
BioCentury | Feb 8, 2019
Product R&D

Reducing R(i)SK in TNBC

...Phoenix Molecular Designs MAPK (ERK) - MAP kinase; PDK - pyruvate dehydrogenase kinase; RSK2 - Ribosomal protein S6...
...Programmed cell death 1 ligand 1 PDK - Pyruvate dehydrogenase kinase RSK2 (RPS6KA3) - Ribosomal protein S6...
...90kDa polypeptide 3 YBX1 (YB1) - Y box binding protein 1 Stephen Hansen, Associate Editor Phoenix Molecular Designs Roche Ribosomal protein S6...
BioCentury | Jan 18, 2019
Company News

Phoenix, Roche partner to develop TNBC biomarker

...cell death 1 ligand 1; RPS6KA3 (RSK2) - Ribosomal protein S6 kinase 90kDa polypeptide 3; RSK - Ribosomal protein S6...
...Molecular Designs, Vancouver, B.C. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Diagnostic Stephen Hansen PMD026 Phoenix Molecular Designs Roche Ribosomal protein S6 kinase (RSK) Ribosomal protein S6...
BioCentury | Jan 17, 2019
Company News

Phoenix, Roche partner to develop TNBC biomarker

...cell death 1 ligand 1; RPS6KA3 (RSK2) - Ribosomal protein S6 kinase 90kDa polypeptide 3; RSK - Ribosomal protein S6...
BioCentury | Jul 20, 2018
Financial News

Hotspot debuts with $45M to find, drug natural allosteric sites

...computer-aided drug design and cellular assays. The company's two lead programs are allosteric inhibitors of ribosomal protein S6...
...joined HotSpot's board. HotSpot Therapeutics Inc., Cambridge, Mass. Karen Tkach Tuzman HotSpot Therapeutics Protein kinase C (PKC) theta (PRKCQ) Ribosomal protein S6...
BioCentury | Jul 17, 2018
Financial News

HotSpot debuts with $45M to find, drug natural allosteric sites

...computer-aided drug design and cellular assays. The company's two lead programs are allosteric inhibitors of ribosomal protein S6...
BioCentury | Jul 17, 2018
Product R&D

Natural spots

...auto-regulated by phosphorylated regulatory tails. PKCθ (PRKCQ) - Protein kinase C θ; S6K1 (RPS6KB1) - Ribosomal protein S6...
...Protein kinase C ι PKCθ (PRKCQ) - Protein kinase C θ S6K1 (RPS6KB1) - Ribosomal protein S6...
...Tuzman, Associate Editor Gain Therapeutics HotSpot Therapeutics Nimbus Discovery LLC Relay Therapeutics Inc. Revolution Medicines Inc. Protein kinase C (PKC) theta (PRKCQ) Ribosomal protein S6...
BioCentury | Apr 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

New Therapeutic Targets and Biomarkers: March 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March 2018. Therapeutic targets are defined as any protein, gene or other...
Items per page:
1 - 10 of 45